Agencies | Governor
Virginia Regulatory Town Hall
Agency
Department of Health Professions
Board
Board of Pharmacy

General Notice
Scheduling chemicals in Schedule I
Date Posted: 7/18/2016
Expiration Date: 9/7/2016
Submitted to Registrar for publication: YES
31 Day Comment Forum closed. Began on 8/1/2016 and ended 9/1/2016

Pursuant to subsection D of § 54.1-3443, the Board of Pharmacy is giving notice of a public hearing to consider placement of chemical substances in Schedule I of the Drug Control Act.  The public hearing will be conducted at 9:00 a.m. on September 7, 2016 at the Perimeter Center, 9960 Mayland Drive, Suite 201, Richmond, VA 23233.  Public comment may also be submitted electronically or in writing prior to June 10, 2016 to Caroline Juran, Executive Director of the Board of Pharmacy to caroline.juran@dhp.virginia.gov.

 As specified in § 54.1-3443, the Virginia Department of Forensic Science (DFS) has identified six (6) compounds for recommended inclusion by the Board of Pharmacy into Schedule I in the Code of Virginia. A brief description and chemical name for each compound is as follows:

 The following compounds are classified as research chemicals. Drugs of this type have been placed in Schedule I (§ 54.1-3446(3)) in previous legislative sessions.

  1. 1-propionyl lysergic acid diethylamide (other name: 1P-LSD)
  1.  (2-Methylaminopropyl)benzofuran (other name: MAPB)

 The following compounds are classified as stimulants. Other drugs of this type have been placed in Schedule I

(§ 54.1-3446(5)) in previous legislative sessions.

  1. Ethyl phenyl(piperidin-2-yl)acetate (other name: Ethylphenidate)
  1. 2-(3-fluorophenyl)-3-methylmorpholine (other name: 3-fluorophenmetrazine)

 The following compounds are powerful synthetic opioids. DFS recommends placing these compounds into Schedule I (§ 54.1-3446(6)).

  1. N-(4-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide

(other name: para-fluorobutyrylfentanyl)

  1. 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]-benzenesulfonamide (other name: W-18)

 If approved by the Board of Pharmacy, the placement of these substances in Schedule I in the Virginia Drug Control Act shall remain in effect for a period of 18 months from the date of Board action and shall then be de-scheduled unless the Drug Control Act is amended by enactment of legislation by the General Assembly.


Contact Information
Name / Title: Caroline Juran, RPh  / Executive Director
Address: 9960 Mayland Drive
Suite 300
Richmond, 23233
Email Address: caroline.juran@dhp.virginia.gov
Telephone: (804)367-4578    FAX: (804)527-4472    TDD: ()-